<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Wang X</submitter><funding>NIDCR NIH HHS</funding><funding>NCI NIH HHS</funding><funding>U.S. Department of Health &amp; Human Services | NIH | National Institute of Dental and Craniofacial Research (NIDCR)</funding><pagination>9968</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12615696</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>16(1)</volume><pubmed_abstract>Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, yet predicting patient response remains a major challenge. Carcinoma ecotypes, which capture the cancer-immune interactions, show promise as prognostic biomarkers but remain untested in real-world settings. We compile and analyze the ORIEN Avatar ICI cohort of 1610 patients with matched gene expression data from a broader dataset of 14,997 individuals. Using EcoTyper-based immunophenotyping, we define ecotypes and assess their prognostic value across cancers, with a focused analysis in melanoma. Distinct cell states and ecotypes are consistently associated with survival outcomes across cancer types. We further develop a melanoma-specific ICI predictive model and validate it using data from the phase III ECOG-ACRIN E1609</pubmed_abstract><journal>Nature communications</journal><pubmed_title>Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors.</pubmed_title><pmcid>PMC12615696</pmcid><funding_grant_id>UG1 CA233324</funding_grant_id><funding_grant_id>U10 CA180794</funding_grant_id><funding_grant_id>UG1 CA233191</funding_grant_id><funding_grant_id>UG1 CA233180</funding_grant_id><funding_grant_id>U10 CA180820</funding_grant_id><funding_grant_id>UG1 CA233184</funding_grant_id><funding_grant_id>U10 CA180821</funding_grant_id><funding_grant_id>U10 CA180888</funding_grant_id><funding_grant_id>UG1 CA233331</funding_grant_id><funding_grant_id>UG1 CA233178</funding_grant_id><funding_grant_id>P30 CA076292</funding_grant_id><funding_grant_id>R01DE030493</funding_grant_id><funding_grant_id>R01 DE030493</funding_grant_id><pubmed_authors>McCarter M</pubmed_authors><pubmed_authors>Eljilany I</pubmed_authors><pubmed_authors>Ratan A</pubmed_authors><pubmed_authors>Agius P</pubmed_authors><pubmed_authors>Sukrithan V</pubmed_authors><pubmed_authors>Marin-Acevedo JA</pubmed_authors><pubmed_authors>Arnold S</pubmed_authors><pubmed_authors>Churchman M</pubmed_authors><pubmed_authors>Radmacher M</pubmed_authors><pubmed_authors>Naqash AR</pubmed_authors><pubmed_authors>Salhia B</pubmed_authors><pubmed_authors>Li T</pubmed_authors><pubmed_authors>Soupir A</pubmed_authors><pubmed_authors>Ganesan S</pubmed_authors><pubmed_authors>Rodriguez PC</pubmed_authors><pubmed_authors>Hwu P</pubmed_authors><pubmed_authors>Colman H</pubmed_authors><pubmed_authors>Dalton WS</pubmed_authors><pubmed_authors>Wang X</pubmed_authors><pubmed_authors>Weiner GJ</pubmed_authors><pubmed_authors>Puzanov I</pubmed_authors><pubmed_authors>Tarhini AA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors.</name><description>Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, yet predicting patient response remains a major challenge. Carcinoma ecotypes, which capture the cancer-immune interactions, show promise as prognostic biomarkers but remain untested in real-world settings. We compile and analyze the ORIEN Avatar ICI cohort of 1610 patients with matched gene expression data from a broader dataset of 14,997 individuals. Using EcoTyper-based immunophenotyping, we define ecotypes and assess their prognostic value across cancers, with a focused analysis in melanoma. Distinct cell states and ecotypes are consistently associated with survival outcomes across cancer types. We further develop a melanoma-specific ICI predictive model and validate it using data from the phase III ECOG-ACRIN E1609</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Nov</publication><modification>2026-06-05T12:09:32.816Z</modification><creation>2026-05-16T03:13:07.697Z</creation></dates><accession>S-EPMC12615696</accession><cross_references><pubmed>41233329</pubmed><doi>10.1038/s41467-025-65016-3</doi></cross_references></HashMap>